To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04826003
Title Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications
Therapies
Age Groups: adult | senior
Covered Countries NLD | GBR | ESP | DNK

Facility Status City State Zip Country Details
Rigshospitalet København Ø 2100 Denmark Details
Severance Hospital, Yonsei University Health System Seoul 03722 Korea, Republic of Details
Asan Medical Center Seoul 05505 Korea, Republic of Details
NKI/AvL Amsterdam 1066 CX Netherlands Details
Clinica Universitaria de Navarra Pamplona Navarra 31008 Spain Details
Hospital del Mar Barcelona 08003 Spain Details
Clinica Universidad de Navarra Madrid Madrid 28027 Spain Details
Fundacion Jimenez Diaz Madrid 28040 Spain Details
Hospital Universitario 12 de Octubre Madrid 28041 Spain Details
Centro Integral Oncologico Clara Campal Madrid 28050 Spain Details
Christie Hospital NHS Trust Manchester M20 4BX United Kingdom Details
Churchill Hospital Oxford OX3 7LJ United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field